NEJM "failed its readers" by delay in publishing its concerns about VIGOR trial.
Dobson
Roger
R
D002986:Clinical Trials as Topic; D052246:Cyclooxygenase 2 Inhibitors / Q000009:adverse effects*; D006801:Humans; D007783:Lactones / Q000009:adverse effects*; D009203:Myocardial Infarction / Q000139:chemically induced*; D010506:Periodicals as Topic; D013450:Sulfones / Q000009:adverse effects*
D052246:Cyclooxygenase 2 Inhibitors; D007783:Lactones; D013450:Sulfones; C116926:rofecoxib